Minireviews
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Virol. Dec 15, 2020; 9(5): 54-66
Published online Dec 15, 2020. doi: 10.5501/wjv.v9.i5.54
Chronic hepatitis B-associated liver disease in the context of human immunodeficiency virus co-infection and underlying metabolic syndrome
Edina Amponsah-Dacosta, Cynthia Tamandjou Tchuem, Motswedi Anderson
Edina Amponsah-Dacosta, Vaccines for Africa Initiative, School of Public Health and Family Medicine, University of Cape Town, Cape Town 7925, Western Cape, South Africa
Cynthia Tamandjou Tchuem, Health Economics Unit, School of Public Health and Family Medicine, University of Cape Town, Cape Town 7925, Western Cape, South Africa
Motswedi Anderson, Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana
Author contributions: Amponsah-Dacosta E defined the topic, performed the literature search and coordinated the writing of the manuscript; Amponsah-Dacosta E, Tamandjou Tchuem C and Anderson M screened and reviewed the literature and wrote the manuscript.
Conflict-of-interest statement: The authors have no conflicts of interest to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Edina Amponsah-Dacosta, PhD, MPH, Postdoctoral Fellow, Vaccines for Africa Initiative, School of Public Health and Family Medicine, University of Cape Town, Anzio Road, Observatory, Cape Town 7925, Western Cape, South Africa. edina.amponsah-dacosta@uct.ac.za
Received: June 26, 2020
Peer-review started: June 26, 2020
First decision: September 21, 2020
Revised: September 24, 2020
Accepted: October 12, 2020
Article in press: October 12, 2020
Published online: December 15, 2020
Processing time: 167 Days and 14.6 Hours
Abstract

Globally, a shift in the epidemiology of chronic liver disease has been observed. This has been mainly driven by a marked decline in the prevalence of chronic hepatitis B virus infection (CHB), with the greatest burden restricted to the Western Pacific and sub-Saharan African regions. Amidst this is a growing burden of metabolic syndrome (MetS) worldwide. A disproportionate co-burden of human immunodeficiency virus (HIV) infection is also reported in sub-Saharan Africa, which poses a further risk of liver-related morbidity and mortality in the region. We reviewed the existing evidence base to improve current understanding of the effect of underlying MetS on the development and progression of chronic liver disease during CHB and HIV co-infection. While the mechanistic association between CHB and MetS remains poorly resolved, the evidence suggests that MetS may have an additive effect on the liver damage caused by CHB. Among HIV infected individuals, MetS-associated liver disease is emerging as an important cause of non-AIDS related morbidity and mortality despite antiretroviral therapy (ART). It is plausible that underlying MetS may lead to adverse outcomes among those with concomitant CHB and HIV co-infection. However, this remains to be explored through rigorous longitudinal studies, especially in sub-Saharan Africa. Ultimately, there is a need for a comprehensive package of care that integrates ART programs with routine screening for MetS and promotion of lifestyle modification to ensure an improved quality of life among CHB and HIV co-infected individuals.

Keywords: Hepatitis B virus; Human immunodeficiency virus; Metabolic syndrome; Fatty liver disease; Chronic liver disease; Sub-Sharan Africa

Core Tip: Independently, chronic hepatitis B virus (HBV) infection, human immunodeficiency virus (HIV) infection and metabolic syndrome (MetS) are known risk factors of chronic liver disease. The presence of MetS components, including type 2 diabetes mellitus, central obesity and lipid abnormalities, are associated with adverse outcomes and altered treatment response among HBV and HIV infected individuals. While underlying MetS may have an additive effect on the development and progression of chronic liver disease among HBV-HIV co-infected individuals, the evidence from endemic regions like sub-Saharan Africa is limited and deserves further attention in the research agenda.